Month: May 2022

COPENHAGEN, Denmark, May 9, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 71,562 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy. The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 5, 2022, according to which the Company may purchase up to 10 % of the Company’s share capital for the time being. The share buy-back program will be executed in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse...

09 May, 2022 – Arcadis (EURONEXT: ARCAD) has been selected to manage the design and development program for Wallbox’s new electric vehicle (EV) charger manufacturing facility in Arlington, Texas, in the U.S. After a collaborative design process, Wallbox began construction of the 130,000 square foot facility in April. The plant will go into production in Q3 and is expected to produce 250,000 units in 2022. By 2025, the facility is expected to produce over 500,000 units annually. Wallbox’s chargers are compatible with all electric vehicles, making the new facility conducive to EV growth in the U.S. In addition to manufacturing, the site will also feature offices, labs, evaluation areas and a warehouse, and is expected to create 250 high-paying green jobs in the region. Ketan Maroo, vice president of industrial infrastructure at Arcadis,...

–Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET-GENEVA, Switzerland May 9, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data from the PRIMROSE (1 and 2) Phase 3 studies of linzagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which was held in San Diego, California from May 6-8, 2022. “We are encouraged by these additional analyses and post-treatment data from the PRIMROSE Phase 3 study that continue to underscore linzagolix’s clinical...

REGULATED INFORMATIONPreliminary documents for the Annual and Extraordinary General Meeting have been made available on company’s websiteMont-Saint-Guibert, Belgium, 9 May 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert, Belgium. Bone Therapeutics also invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the extraordinary general meeting which will be held on the same day as from 6:00 pm CEST, at Rue...

EfTEN Capital AS (registry code 11505542, address A. Lauteri tn 5, 10114 Tallinn) as the management company of the EfTEN United Property Fund announces a public offering of the units of the EfTEN United Property Fund. Offering of units The Management Company organizes the offering of up to 500,000 fund units to all natural and legal persons in Estonia in accordance with the public offering prospectus of the units. The offer is divided to interim periods. During the first interim period, i.e. from 9.00 am (EET) on 09.05.2022 to 11.00 am on 20.05.2022 (EET), the Management Company will offer and the Fund will issue 460,000 offered units. The Management Company has the right to increase the offer by 300,000 offered units during the first interim period. From the second interim period until the end of the offer period, i.e. from 9.00 am (EET)...

VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer VB10.16 in combination with atezolizumab demonstrated a very high DCR of 64% Anti-tumor activity of VB10.16 in combination with atezolizumab was observed both in PD-L1 positive patients (ORR of 27%; DCR of 77%) and PD-L1 negative patients (ORR of 17%; DCR of 58%) Management to host webcast presentation of the interim results today, May 9, 2022 at 2 p.m. CET / 8 a.m. ET OSLO, Norway, May 09, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced positive interim results from its Phase...

Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing MENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with genome analysis company iLAC, Inc. (iLAC) and Robotic Biology Institute, Inc. (RBI) to develop fully automated end-to-end workflows for PacBio’s Sequel II and Sequel IIe HiFi long-read sequencing systems by employing advanced robotics. Using technical information and feedback from PacBio, iLAC and RBI will work together to develop and validate automated high-throughput solutions on RBI’s LabDroid robotic system for deployment at iLAC’s genomic services facility in Tsukuba, Japan. These automated workflows will...